Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Merck
Harvard Business School
Mallinckrodt
McKesson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Staurosporine

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Staurosporine?

Staurosporine is an investigational drug.

There have been 29 clinical trials for Staurosporine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), University Health Network, Toronto, and Memorial Sloan Kettering Cancer Center.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Staurosporine
TitleSponsorPhase
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeNational Cancer Institute (NCI)Phase 2/Phase 3
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantNational Cancer Institute (NCI)Phase 2
Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantStanford UniversityPhase 2

See all Staurosporine clinical trials

Clinical Trial Summary for Staurosporine

Top disease conditions for Staurosporine
Top clinical trial sponsors for Staurosporine

See all Staurosporine clinical trials

US Patents for Staurosporine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Staurosporine   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Staurosporine   Start Trial Substituted indole Mcl-1 inhibitors Vanderbilt University (Nashville, TN)   Start Trial
Staurosporine   Start Trial Tapered looped suture Covidien LP (Mansfield, MA)   Start Trial
Staurosporine   Start Trial Compositions and methods for inhibiting intimal hyperplasia   Start Trial
Staurosporine   Start Trial Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Staurosporine

Drugname Country Document Number Estimated Expiration Related US Patent
Staurosporine Australia 2006269422 2025-07-07   Start Trial
Staurosporine Canada 2614436 2025-07-07   Start Trial
Staurosporine European Patent Office 1917020 2025-07-07   Start Trial
Staurosporine European Patent Office 2722051 2025-07-07   Start Trial
Staurosporine European Patent Office 3498289 2025-07-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
Harvard Business School
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.